Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid®) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

NCT00179725 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.

NCT NCT00179725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00179725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid®) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
Lead sponsor
Celgene Corporation
Phase
Phase 1/2
Overall status
Terminated
Start date
November 30, 2005
Completion date
June 30, 2007
Enrollment
60
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer